• Title/Summary/Keyword: therapeutic efficacy

Search Result 956, Processing Time 0.024 seconds

Impacts of glycans attached to therapeutic glycoproteins (의약용 당단백질에 부가된 당사슬의 중요성)

  • Kim, Seong-Hun;Kwon, Oh-Suk;Oh, Doo-Byoung
    • Journal of Plant Biotechnology
    • /
    • v.37 no.3
    • /
    • pp.292-304
    • /
    • 2010
  • High value-added therapeutic proteins have been leading the biologics industry and occupied major portion of the market. More than 60% of the currently available protein therapeutics are glycoproteins attached with glycans which play crucial roles for the protein folding, therapeutic efficacy, in vivo half-life and immunogenecity. This review introduces the process of glycosylation and the impacts of glycans in the aspects of therapeutics. The important glycan structures in therapeutic performances were also summarized focusing on three representative categories of glycoproteins, cytokines, therapeutic antibody and enzyme. Currently, mammalian expression systems such as Chinese hamster ovary cells are preferred for the production of therapeutic glycoproteins due to their ability to synthesize glycans having similar structures with human type glycans. However, recent advances of plant glycoengineering to overcome the limitation originating from different glycan structures will soon allow to develop more efficient and economic plant-based production systems for therapeutic glycoproteins.

A Clinical Therapeutic Guideline of Antipsychotic Drugs (항정신병약물의 임상치료지침)

  • Yoon, Doh-Joon
    • Korean Journal of Biological Psychiatry
    • /
    • v.1 no.1
    • /
    • pp.7-16
    • /
    • 1994
  • I will try to serve as the basis for the development of a clinical therapeutic guideline of antipsychotic drugs. Knowing that many patients fail standard treatment recommendations, either because of insufficient efficacy or intolerance to adverse effects, led us to emphasize the importance of the guideline. The clinicians continually assimilate new information about recent advances, including : novel agents targeted to impact specific components of various neurotransmitter systems ; combination strategies ; alternative uses of existing agents ; and specialized requirements of a growing number of identified diagnostic subtypes. The cost to benefit ratio must always be considered when developing a therapeutic guideline.

  • PDF

Literature Review on Biological Effects of Gyejibokryeong-hwan against Gynaecological Diseases

  • Kim, Jung-Hoon;Shin, Hyeun-Kyoo
    • The Journal of Korean Medicine
    • /
    • v.34 no.2
    • /
    • pp.29-40
    • /
    • 2013
  • Objectives: To investigate therapeutic mechanisms of Gyejibokryeong-hwan (GJBRH) against gynaecological diseases, articles on biological assay were gathered and analyzed. Methods: The articles were classified as being from domestic or international journals, and by their year of publication. The mechanisms of the biological effects against gynaecological diseases were noted. Results: Of the 14 articles analyzed, 13 were published in China and 1 was from Japan. GJBRH showed therapeutic effect against uterine and mammary gland diseases. Uterine-related diseases such as endometriosis, hysteromyoma, adenomyosis, cancer, and inflammation can be improved by the administration of GJBRH through anti-angiogenesis, anti-inflammation, the modulation of immune cell and immunoglobulin, and the regulation of hormone secretion. GJBRH also reduced mammary hyperplasia by regulating hormone and cytokine release. Conclusions: We speculate that the inhibitory effect against uterine and mammary gland diseases could be related to the therapeutic efficacy of GJBRH in improving gynaecological diseases.

Therapeutic Drug Monitoring (TDM) of Psychotropic Drugs (향정신성약물의 치료적 약물농도 검사)

  • Yang, Byung-Hwan
    • Korean Journal of Biological Psychiatry
    • /
    • v.5 no.1
    • /
    • pp.56-65
    • /
    • 1998
  • Clinicians can use therapeutic drug monitoring(TDM) to optimise dosage decisions with psychotropic drugs, in order to maximize efficacy and prevent toxicity, especially when individuals are nonresponsive to treatment or vulnerable to adverse reactions with standard doses because age, disease states or drug interactions. Currently, therapeutic drug concentrations have been established for the TCA and lithium. There is also evidence for the usefulness of TDM with carbamazepine, valproic acid and some antipsychotic drugs. However for most psychotropic drugs this approach remains experimental. TDM-assisted psychiatric treatment is potentially useful and cost effective, particularly when applied by psychiatrists who are knowledgeable of pharmacokinetics and pharmacodynamics.

  • PDF

PEGYLATION: Novel Technology to Enhance Therapeutic Efficacy of Proteins and Peptides (PEG 접합: 단백질 및 펩타이드 치료제의 약효를 증가시키는 새로운 기술)

  • Park, Myung-Ok;Lee, Kang-Choon
    • Journal of Pharmaceutical Investigation
    • /
    • v.30 no.2
    • /
    • pp.73-83
    • /
    • 2000
  • Polyethylene glycol (PEG) is a water soluble, biocompatible, non-toxic polymer and PEGylation is a well established technique for the modification of therapeutic proteins and peptides. PEG-protein drugs have been extensively studies in relation to therapies for various diseases: cancer, inflammation and others. The covalent attachment of PEG to proteins and peptides prolonged plasma half-life, reduced antigenicity and immunogenicity, increased thermal and mechanical stability, and prevented degradation by enzymes. Several chemical groups for general and site specific conjugation have been exploited to activate PEG for amino group, carboxyl group, and cysteine groups. PEGylation of many proteins and peptides have been studied to enhance their properties for the potential uses. Also, the different positional isomers in several PEG-proteins have shown the difference in vivo stability and biological indicating that the site of PEG molecule attachment is one of the important factor to develop PEG-proteins as potential therapeutic agents.

  • PDF

Comparative Efficacy Study of Pyeongwi-san(Pingwei-san) of Digestive Tract Disease Model in Rat (소화기 질환 동물모델에서 평위산(平胃散)의 염증 완화 효과)

  • Jung, Seyoung;Jung, Sung Eun;Kim, Ji Hye;Ham, Seong Ho;Yang, Woong Mo;Kwon, Bo-In
    • The Korea Journal of Herbology
    • /
    • v.35 no.2
    • /
    • pp.7-14
    • /
    • 2020
  • Objectives : Pyeongwi-san is widely used in Korean medicine for acute indigestion or gastrodynia. As a therapeutic agent for digestive diseases of modern people, in order to confirm the mechanism of Pyeongwi-san on digestive tract disease and the difference of therapeutic efficacy between its formulation, a comparative efficacy test was conducted on digestive tract disease animal model. Methods : For LPS enteritis animal model, male SD rats were intraorally treated with different formulation types of Pyeongwi-san, and then intraperitoneally administered LPS one hour later to induce enteritis. After 5 hours, blood was collected and TNFα, IL-1β, IL-6 and PGE2 were confirmed by ELISA. For acute gastritis animal model, male SD rats were intraorally treated with different formulation types of Pyeongwi-san according to the prescribed concentration, and then intraorally administered 60% ethanol and 150 mM HCl one hour later to induce acute gastritis. After 5 hours, blood was collected and TNFα,IL-6 were confirmed by ELISA. Results : In the LPS-administered enteritis animal model, Pyeongwi-san decreased TNFα, IL-1β, PGE2 and especially IL-6. Pyeongwi-san also decreased IL-6 in acute gastritis animal model. In addition, there was no significant difference in efficacy between the two formulations when compared with inflammatory markers. Conclusions : The efficacy of Pyeongwi-san was confirmed in the inflammatory markers related to digestive inflammatory diseases, and the efficay between two formulations of Pyeongwi-san was relatively similar. Further studies are needed to investigate the new applicability of Pyeongwi-san on different inflammatory diseases that have similar inflammation markers identified in this experiment.

Mizoribine Inhibits Production of Pro-inflammatory Cytokines and $PGE_2$ in Macrophages

  • Han, Shin-Ha;Kim, Kwang-Hee;Kim, Hyun-Yul;Kwon, Jeung-Hak;Han, Nam-Joo;Lee, Chong-Kil;Kim, Kyung-Jae
    • IMMUNE NETWORK
    • /
    • v.7 no.1
    • /
    • pp.31-38
    • /
    • 2007
  • Background: Mizoribine (MZR) is an imidazole nucleoside isolated from Eupenicillium brefeldianum. MZR is currendy in clinical use for patients who have undergone renal transplantation. Therapeutic efficacy of MZR has also been demonstrated in rheumatoid arthritis and lupus nephritis. MZR has been shown to inhibit the proliferation or lymphocytes by interfering with inosine monophosphate dehydrogenase. Since the exact mechanism by which MZR benefits rheumatoid arthritis (RA) is not clear, we investigated the ability of MZR to direct its immunosuppressive influences on other antigen presenting cells, such as macrophages. Methods: Mouse macrophage RAW264.7 cells were stimulated with lipopolysaccharide in the presence of MZR. To elucidate the mechanism of the therapeutic efficacy in chronic inflammatory diseases, we examined the effects of MZR on the production of pro-inflammatory cytokines, nitric oxide (NO) and prostaglandin $E_2\;(PGE_2)$ in macrophages. Results: MZR dose-dependendy decreased the production of nitric oxide and pro- inflammatory cytokines such as tumor necrosis factor-${\alpha}$ (TNF-${\alpha}$), interleukins $1{\beta}$ (IL-${\beta}$ and IL-6 $PGE_2$. Examination of gene expression levels showed that the anti-inflammatory effect correlated with the down-regulation of inducible nitiric oxide synthase expression, cycloxygenase-2 expression and TNF-${\alpha}$ gene expression. Conclusion: In this work, we resulted whether MZR $(1.25{\sim}10{\mu}g/ml)$ inhibited macrophage activation by inhibiting secretion of pro-inflammatory cytokines, NO and $PGE_2$. These findings provide an explanation for the therapeutic efficacy of MZR in chronic inflammation-associated diseases.

Jn vivo and Jn vivo Antibacterial Activity of DW-ll6, a New Quinolone Antibiotic (신규 퀴놀론 항균제 DW-116의 in vivo 및 in vivo 항균활성)

  • Hwang, Yun-Ha;Han, Kyung-Oh;Lee, Jin;Yang, Hee-Bog;Chung, Yong-Ho;Yoon, Sung-June;Lee, Dug-Keun
    • Biomolecules & Therapeutics
    • /
    • v.5 no.2
    • /
    • pp.187-193
    • /
    • 1997
  • The in vivo and in vivo antibacterial activity of DW-116, a newly synthesized fluoroquinolone, were compared with those of other quinolones. DW-116 exhibited more potent antibacterial activity than rufloxacin and lower activity than ofloxacin and ciprofloxacin in in vivo assay But, DW-116 particularly showed strong activity against the family of staphylococci including methicillin-sensitive staphylococcus and its activity was more active than that of ciprofloxacin. The time-kill curve studies showed rapid bactericidal activity for DW-116. The post-antibiotic effect of DW-116 was observed between 0.66 and 5 hours. The therapeutic efficacy of DW-116 against respiratory infection with P. aeruginosa was as strong as that of ciprofloxacin and its effect against urinary tract in(traction with E. coli was more effective than rufloxacin. The excellent therapeutic efficacy of DW-116 against these local infections is due to its good pharmacokinetic profiles.

  • PDF

Prophylactic and Therapeutic Potential of Asp f1 Epitopes in Naive and Sensitized BALB/c Mice

  • Chaudhary, Neelkamal;Mahajan, Lakshna;Madan, Taruna;Kumar, Anil;Raghava, Gajendra Pratap Singh;Katti, Seturam Bandacharya;Haq, Wahajul;Sarma, Puranam Usha
    • IMMUNE NETWORK
    • /
    • v.9 no.5
    • /
    • pp.179-191
    • /
    • 2009
  • Background: The present study examines a hypothesis that short allergen-derived peptides may shift an Aspergillus fumigatus (Afu-) specific TH2 response towards a protective TH1. Five overlapping peptides (P1-P5) derived from Asp f1, a major allergen/antigen of Afu, were evaluated for prophylactic or therapeutic efficacy in BALB/c mice. Methods: To evaluate the prophylactic efficacy, peptides were intranasally administered to naive mice and challenged with Afu-allergens/antigens. For evaluation of therapeutic efficacy, the mice were sensitized with Afu-allergens/antigens followed by intranasal administration of peptides. The groups were compared for the levels of Afu-specific antibodies in sera and splenic cytokines evaluated by ELISA. Eosinophil peroxidase activity was examined in the lung cell suspensions and lung inflammation was assessed by histopathogy. Results: Peptides P1-, P2- and P3 decreased Afu-specific IgE (84.5~98.9%) and IgG antibodies (45.7~71.6%) in comparison with Afu-sensitized mice prophylactically. P1- and P2-treated ABPA mice showed decline in Afu-specific IgE (76.4~88%) and IgG antibodies (15~54%). Increased IgG2a/IgG1 and IFN-${\gamma}$/IL-4 ratios were observed. P1-P3 prophylactically and P1 therapeutically decreased IL-5 levels and eosinophil peroxidase activity. P1 decreased inflammatory cells' infiltration in lung tissue comparable to non-challenged control. Conclusion: Asp f1-derived peptide P1, prophylactically and therapeutically administered to Balb/c mice, is effective in regulating allergic response to allergens/antigens of Afu, and may be explored for immunotherapy of allergic aspergillosis in humans.

Therapeutic Efficacy of Extracts from Root of Acnthopanax Sessiliflorus as Anti-cancer Drug ; in vivo and in vitro Study

  • Kim, Hyung-Woo;Jeong, Sun;Baek, Gwang-Hyun;Cho, Su-In;Jeon, Byung-Gwan;Kim, Gye-Yeop;Cho, Young-Lim;Jeong, Hyun-Woo
    • Journal of Physiology & Pathology in Korean Medicine
    • /
    • v.21 no.2
    • /
    • pp.518-522
    • /
    • 2007
  • The cortex and root of Acnthopanax sessiliflorus, a herbal medicine, have been used for several diseases including cancer in Oriental countries. In the previous study, we showed that the cortex of this plant have anti-cancer activity. But its therapeutic efficacy of CORTEX ACANTHOPANAX RADICIS (CAR) is not clarified. For these reasons, we investigated immuno-potentiating and anti-cancer properties of CAR compared with CA, in terms of body and tumor weights, proliferation of thymocytes and tumor cells, and nitric oxide production from macrophages through in vitro and in vivo studies. In our results, administration of CAR reduced tumor mass and increased body weights. CAR also inhibited proliferation of tumor cells in vivo and in vitro dose-dependently. Thymocyte proliferation was accelerated by treatment with CAR and NO production was also promoted by CAR in vivo and vitro. In conclusion, we demonstrated that CAR is useful to treat for cancer as complementary or alternative medicine to Western medication, its therapeutic efficacy is involved in direct inhibition of tumor growth and immuno-potentiating activity.